These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27430370)

  • 1. Purity of transferred CD8(+) T cells is crucial for safety and efficacy of combinatorial tumor immunotherapy in the absence of SHP-1.
    Watson HA; Dolton G; Ohme J; Ladell K; Vigar M; Wehenkel S; Hindley J; Mohammed RN; Miners K; Luckwell RA; Price DA; Matthews RJ; Ager A
    Immunol Cell Biol; 2016 Sep; 94(8):802-8. PubMed ID: 27430370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of SHP-1 Expands the Repertoire of Antitumor T Cells Available to Respond to Immune Checkpoint Blockade.
    Snook JP; Soedel AJ; Ekiz HA; O'Connell RM; Williams MA
    Cancer Immunol Res; 2020 Apr; 8(4):506-517. PubMed ID: 32075800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
    Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
    Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abrogation of SRC homology region 2 domain-containing phosphatase 1 in tumor-specific T cells improves efficacy of adoptive immunotherapy by enhancing the effector function and accumulation of short-lived effector T cells in vivo.
    Stromnes IM; Fowler C; Casamina CC; Georgopolos CM; McAfee MS; Schmitt TM; Tan X; Kim TD; Choi I; Blattman JN; Greenberg PD
    J Immunol; 2012 Aug; 189(4):1812-25. PubMed ID: 22798667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SHP-1 phosphatase activity counteracts increased T cell receptor affinity.
    Hebeisen M; Baitsch L; Presotto D; Baumgaertner P; Romero P; Michielin O; Speiser DE; Rufer N
    J Clin Invest; 2013 Mar; 123(3):1044-56. PubMed ID: 23391724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SHP-1 in T cells limits the production of CD8 effector cells without impacting the formation of long-lived central memory cells.
    Fowler CC; Pao LI; Blattman JN; Greenberg PD
    J Immunol; 2010 Sep; 185(6):3256-67. PubMed ID: 20696858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects.
    Kujawski M; Zhang C; Herrmann A; Reckamp K; Scuto A; Jensen M; Deng J; Forman S; Figlin R; Yu H
    Cancer Res; 2010 Dec; 70(23):9599-610. PubMed ID: 21118964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma.
    Kodumudi KN; Weber A; Sarnaik AA; Pilon-Thomas S
    J Immunol; 2012 Dec; 189(11):5147-54. PubMed ID: 23100512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of IL-2- versus IL-15-stimulated CD8 T cells in adoptive immunotherapy.
    Mueller K; Schweier O; Pircher H
    Eur J Immunol; 2008 Oct; 38(10):2874-85. PubMed ID: 18825743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterodimeric IL15 Treatment Enhances Tumor Infiltration, Persistence, and Effector Functions of Adoptively Transferred Tumor-specific T Cells in the Absence of Lymphodepletion.
    Ng SSM; Nagy BA; Jensen SM; Hu X; Alicea C; Fox BA; Felber BK; Bergamaschi C; Pavlakis GN
    Clin Cancer Res; 2017 Jun; 23(11):2817-2830. PubMed ID: 27986749
    [No Abstract]   [Full Text] [Related]  

  • 11. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts.
    Kerkar SP; Muranski P; Kaiser A; Boni A; Sanchez-Perez L; Yu Z; Palmer DC; Reger RN; Borman ZA; Zhang L; Morgan RA; Gattinoni L; Rosenberg SA; Trinchieri G; Restifo NP
    Cancer Res; 2010 Sep; 70(17):6725-34. PubMed ID: 20647327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SHP-1: the next checkpoint target for cancer immunotherapy?
    Watson HA; Wehenkel S; Matthews J; Ager A
    Biochem Soc Trans; 2016 Apr; 44(2):356-62. PubMed ID: 27068940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of Src homology region 2 domain-containing protein tyrosine phosphatase-1 increases CD8+ T cell-APC conjugate formation and is associated with enhanced in vivo CTL function.
    Sathish JG; Dolton G; Leroy FG; Matthews RJ
    J Immunol; 2007 Jan; 178(1):330-7. PubMed ID: 17182570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour.
    Song S; Zhang K; You H; Wang J; Wang Z; Yan C; Liu F
    Clin Exp Immunol; 2010 Oct; 162(1):75-83. PubMed ID: 20735440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.
    Pilon-Thomas S; Mackay A; Vohra N; Mulé JJ
    J Immunol; 2010 Apr; 184(7):3442-9. PubMed ID: 20194714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.
    Kjaergaard J; Peng L; Cohen PA; Drazba JA; Weinberg AD; Shu S
    J Immunol; 2001 Dec; 167(11):6669-77. PubMed ID: 11714839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blocking initial infiltration of pioneer CD8(+) T-cells into the CNS via inhibition of SHP-2 ameliorates experimental autoimmune encephalomyelitis in mice.
    Luo Q; Sun Y; Gong FY; Liu W; Zheng W; Shen Y; Hua ZC; Xu Q
    Br J Pharmacol; 2014 Apr; 171(7):1706-21. PubMed ID: 24372081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.
    Antony PA; Piccirillo CA; Akpinarli A; Finkelstein SE; Speiss PJ; Surman DR; Palmer DC; Chan CC; Klebanoff CA; Overwijk WW; Rosenberg SA; Restifo NP
    J Immunol; 2005 Mar; 174(5):2591-601. PubMed ID: 15728465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice.
    Bullock TN; Mullins DW; Colella TA; Engelhard VH
    J Immunol; 2001 Nov; 167(10):5824-31. PubMed ID: 11698456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
    Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C
    Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.